MARKET

AVEO

AVEO

Aveo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.89
+0.27
+4.08%
After Hours: 6.78 -0.11 -1.60% 19:49 09/17 EDT
OPEN
6.61
PREV CLOSE
6.62
HIGH
6.90
LOW
6.60
VOLUME
422.23K
TURNOVER
--
52 WEEK HIGH
18.24
52 WEEK LOW
4.950
MARKET CAP
236.84M
P/E (TTM)
-3.5064
1D
5D
1M
3M
1Y
5Y
Great news for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): Insiders acquired stock in large numbers last year
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Simply Wall St. · 4d ago
A Trio of Stocks Growing Capex Fast
GuruFocus News · 09/09 15:53
Aveo Pharmaceuticals Inc (AVEO) President & CEO Michael P Bailey Bought $97,200 of Shares
GuruFocus News · 09/03 04:08
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
BOSTON, August 30, 2021--AVEO Oncology (Nasdaq: AVEO) today announced that members of its senior management team will participate in two upcoming virtual investor conferences:
Business Wire · 08/30 11:00
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates
Zacks.com · 08/05 22:45
Recap: AVEO Pharmaceuticals Q2 Earnings
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 4.76% year over year to ($0.40), which beat the estimate of ($0.45).
Benzinga · 08/05 21:42
AVEO Pharmaceuticals EPS beats by $0.10, beats on revenue
AVEO Pharmaceuticals (NASDAQ:AVEO): Q2 GAAP EPS of -$0.40 beats by $0.10. Revenue of $7.6M (+913.3% Y/Y) beats by $0.64M. AVEO believes its $102.9M in cash, cash equivalents and marketable securities
Seekingalpha · 08/05 21:25
BRIEF-Aveo Pharmaceuticals Q2 Loss Per Share $0.40
reuters.com · 08/05 21:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVEO. Analyze the recent business situations of Aveo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVEO stock price target is 20.00 with a high estimate of 24.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 121
Institutional Holdings: 15.87M
% Owned: 46.16%
Shares Outstanding: 34.37M
TypeInstitutionsShares
Increased
14
1.96M
New
17
2.33M
Decreased
24
2.92M
Sold Out
26
902.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Director
Michael Bailey
Chief Financial Officer
Erick Lucera
Other
Michael Ferraresso
Other
Michael Needle
Independent Director
Kevin Cullen
Independent Director
Corinne Epperly
Independent Director
Anthony Evnin
Independent Director
Gregory Mayes
Independent Director
Scarlett Spring
No Data
  • All
  • Financials
  • Insiders
More
About AVEO
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Webull offers kinds of AVEO Pharmaceuticals, Inc. stock information, including NASDAQ:AVEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVEO stock methods without spending real money on the virtual paper trading platform.